TickerFacts.

ADMA Biologics, Inc. (ADMA): Long-Term Debt

Annual figures by period end, from SEC filings.

$72.14M
As of 2025-12-31
$196.59M
As of 2026-06-30
$72.34M2016-12-31: $1.79M2017-12-31: $2.76M2018-12-31: $2.76M2019-12-31: $02024-12-31: $72.34M2025-12-31: $72.14M$72.14M
2016-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$72.14M-0.3%2026-02-25, Balance as of period end
2024-12-31$72.34Mn/a2026-02-25, Balance as of period end
No annual figure between 2019-12-31 and 2024-12-31.
2019-12-31$0-100.0%2020-03-13, Balance as of period end
2018-12-31$2.76M0.0%2020-03-13, Balance as of period end
2017-12-31$2.76M+54.2%2019-03-13, Balance as of period end
2016-12-31$1.79Mn/a2018-03-29, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
ADMA Biologics, Inc. (ADMA)2025-12-31$72.14M-0.3%
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$72.44M+0.8%
Repligen Corp (RGEN)2025-12-31$542.21M+3.2%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$2.14B+42.3%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$54.28Mn/a
Qiagen N.V. (QGEN)2025-12-31$1.65B+18.9%
Agenus Inc (AGEN)2025-12-31$44.66M+34.6%
Fennec Pharmaceuticals Inc. (FENC)2024-12-31$19.34M-37.5%
Editas Medicine, Inc. (EDIT)2024-12-31$57.43Mn/a

Compare ADMA, TARS, RGEN, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗